Press Releases
Site - Investor Relations
Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer outcomes
These developments represent an important step forward in oncology. There are currently no biomarkers for prognosis and treatment responses in ovarian cancer, making it challenging to tailor treatments to individual patients. Doctors must choose from a set ‘menu’ of drugs and therapies that have not changed much in the last two decades, despite extensive research efforts. The Helomics AI model has the potential to be used to narrow down ovarian cancer treatment choices as it predicts patients’ responses to specific therapies, improving patients’ prognosis and offering clinicians a more efficient and cost-effective precision medicine approach to treatment. Importantly, these models also provide doctors and scientists better insights into which genes are involved in response to treatment, allowing for the development of new precision medicines.
About
About
About Genomics England
Genomics
Genomics
Forward-Looking Statements
Certain Matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would’” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements because of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the
Investor Relations Contact
(404)995-6671
kpinder@landoncapital.net
Source: Predictive Oncology Inc.